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Abstract
Background: Measuring progress towards the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90–90–90
treatment targets is key to assessing progress towards turning the HIV epidemic tide. In 2017, the UNAIDS model
estimated that 75% of people living with HIV (PLHIV) globally knew their HIV positive status, 79% of those who
knew their status were on antiretroviral therapy (ART), and 81% of those who knew their HIV status and were on
ART had a suppressed viral load. The fifth South African national HIV sero-behavioural survey collected nationally
representative data that enabled the empirical estimation of these 90–90–90 targets for the country stratified by a
variety of key factors.
Methods: To evaluate progress towards achievement of the 90–90–90 targets for South Africa, data obtained from
a national, representative, cross-sectional population-based multi-stage stratified cluster random survey conducted
in 2017 were analysed. The Fifth South African National HIV Prevalence, Incidence, Behaviour and Communication
Survey (SABSSM V), collected behavioural and biomarker data from individuals residing in households from 1000
randomly selected Small Area Layers (SALs), across all nine provinces of the country. Structured questionnaires were
used to collect socio-demographic data, knowledge and perceptions about HIV, and related risk behaviours. Blood
samples were collected to test for HIV infection, antiretroviral use, and viral suppression (defined as < 1000 copies/
ml). Weighted proportions of study participants aged 15 years and older who tested HIV positive were computed
for those who reported awareness of their status (1st 90), and among these, those who were currently on ART (2nd
90) and of these, those who were virally suppressed (3rd 90).
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Results: Among persons 15 years and older who were HIV positive, 84.8% were aware of their HIV positive status, of
whom 70.7% were currently on ART, with 87.4% of these estimated to have suppressed viral load at the time of the
survey. These estimates varied by sex, age, and geo-location type. Relatively higher percentages across all three
indicators for women compared to men were observed: 88.7% versus 78.2% for those aware of their status, 72.3%
versus 67.7% for on ART, and 89.8% versus 82.3% for viral suppression. Knowing one’s positive HIV status increased
with age: 74.0, 85.8, and 88.1% for age groups 15–24 years old, 25–49 years old and 50–64 years old, although for
those 65 years and older, 78.7% knew their HIV positive status. A similar pattern was observed for the 2nd 90,
among those who knew their HIV positive status, 51.7% of 15 to 24 year olds, 70.5% of those aged 25–49 years old,
82.9% of those aged 50–64 years old and 82.4% of those aged 65 years or older were currently on ART. Viral
suppression for the above mentioned aged groups, among those who were on ART was 85.2, 87.2, 89.5, and 84.6%
respectively. The 90–90–90 indicators for urban areas were 87.7, 66.5, and 87.2%, for rural settings was 85.8, 79.8,
and 88.4%, while in commercial farming communities it was 56.2, 67.6 and 81.4%.
Conclusions: South Africa appears to be on track to achieve the first 90 indicator by 2020. However, it is behind on
the second 90 indicator with ART coverage that was ~ 20-percentage points below the target among people who
knew their HIV status, this indicates deficiencies around linkage to and retention on ART. Overall viral suppression
among those on ART is approaching the target at 87.4%, but this must be interpreted in the context of low
reported ART coverage as well as with variation by age and sex. Targeted diagnosis, awareness, and treatment
programs for men, young people aged 15–24 years old, people who reside in farming communities, and in specific
provinces are needed. More nuanced 90–90–90 estimates within provinces, specifically looking at more granular
sub-national level (e.g. districts), are needed to identify gaps in specific regions and to inform provincial
interventions.
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Background
The 90–90–90 targets are that 90% of people living with
HIV (PLHIV) know their HIV status, 90% of people who
know their status be on antiretroviral (ARVs), and 90%
of all patients receiving antiretroviral therapy (ART) are
virally suppressed by 2020 [28]. Modelling exercises
showed that achievement of these targets could reduce
the number of new infections to levels that may achieve
HIV/AIDS epidemic control by 2030 [27].
The HIV epidemic in South Africa, with its estimated
7.1 million PLHIV, accounted for approximately 20% of
the 36.9 million PLHIV in the world in 2017 [28]. In that
year, the global 90–90–90 indicators were modelled at
75, 79, and 81% for those who knew their HIV status,
those on ART who knew their status, and those who
had suppressed viral load who were on ART and knew
their HIV status, respectively [28]. For South Africa,
modelled estimates from the 2015 Thembisa model esti-
mate the indicators at: 85.5, 56.9, and 78.4% [9]. Evaluat-
ing the 90–90–90 indicators within South Africa is
critical in ensuring progress towards achieving these tar-
gets to curb the HIV epidemic nationally and worldwide.
In 2015, the World Health Organisation (WHO) rec-
ommended that HIV ARV treatment should start as
soon as possible after diagnosis of HIV infection regard-
less of CD4 count and/or WHO clinical stage [29]. This
recommendation, referred to as Universal Test and
Treat (UTT), was informed by several studies that
showed that early access to ART reduces viral load to
very low or undetectable levels, resulting in better health
outcomes ([6, 23] and a reduced risk of onward trans-
mission of the virus [21, 26]. South Africa adopted the
UTT strategy and rolled out UTT guidelines for the
public healthcare sector in September 2016 [17].
Several multi-country studies inclusive of South Afri-
can sites have evaluated UTT using the 90–90–90 tar-
gets. Hayes et al. [7], estimated that 78% of men and
87% of women were aware of their HIV-positive status
(i.e. 1st 90) of which 74% of men and 73% of women
were on ART (i.e. 2nd 90). Relative to the 90–90–90 cas-
cade measure, the overall percentage of people on ART
among all PLHIV was 61% a year after the intervention
had started. In the Treatment as Prevention (TasP) trial,
92% of PLHIV indicated that they knew their HIV status,
but only 49% were on ART with 93% of these having
achieved viral suppression [8]. These studies cover spe-
cific geographic areas rather than national in scope.
The Human Sciences Research Council undertook the
Fifth South African National HIV Prevalence, Incidence,
Behaviour and Communication Survey (SABSSM V) in
2017/8 [25]. This is the fifth in a series of cross-sectional
population-based household surveys. Previously such
surveys were completed in 2002, 2005, 2008, and 2012.
The current survey provides an opportunity to report on
the progress of South Africa towards achieving the 90–
90–90 targets using data collected from a population-
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based nationally representative sample following the roll-
out of UTT nationwide.
Methods
Details on the SABSSM survey methodology have been
described elsewhere [25]. In summary, the South African
2015 national population survey sampling frame was
used to randomly select 1000 small area layers (SALs)
from a total 103,000 SALs nationwide as defined by Sta-
tistics South Africa (STATS-SA, 2017). The sample was
further stratified by province and locality type (urban,
rural, and farming communities). From each SAL, 15
households or visiting points (VPs) were selected using
systematic sampling to identify and enroll individuals
into the survey. All members of selected households
were invited to participate in the survey. The study ex-
cluded facilities and individuals living in education insti-
tutions, assisted living homes, hospitals, and those living
in uniformed-service barracks. A total of 12,435 VPs
from the target of 15,000 (82.9%) VPs were approached,
and 11,776 (94.7%) were determined to be valid VPs. A
VP was invalid if the selected house was demolished, no
one lived in it, or if it was a non-residential structure.
Amongst all valid households, 82.2% of household heads
gave permission for their households to take part in the
survey. Data collection took place from November 2017
to March 2018.
The study received ethical clearance from the Human
Sciences Research Council Research Ethics Committee
(REC 4/18/11/15) and The US Centers for Disease Con-
trol (CDC). In compliance to this ethical clearance,
adults, 18 years or older provided written informed con-
sent, while for children, younger than 18 years old, par-
ental/guardian informed written consent and the minor’s
assent were obtained before participants took part in the
study. Household data for socio-demographic character-
istics such as age, sex, race, education, and household as-
sets were collected. Individual level data were also
collected on health, sexual behavior, knowledge and per-
ception of HIV and TB. Dried Blood Spots (DBS) were
also collected to test for HIV status, recency of infection,
exposure to antiretroviral (ARV) drugs, ART resistance,
and levels of viral suppression. For this analysis, data for
individuals aged 15 years and older were used.
HIV, ART and viral load testing
Dried Blood Spot (DBS) samples were used for national
and sub-national estimates of HIV prevalence, incidence,
ARV exposure, HIV drug resistance, and viral suppres-
sion. DBS samples were collected by finger prick from
consenting individuals. To test for HIV infection, three
enzyme immunoassays (EIA) (Roche Elecys HIV Ag/Ab
assay, Roche Diagnostics, Mannheim, Germany and
Genescreen Ultra HIV Ag/Ab assay, Bio-Rad
Laboratories, California, USA) were used. Two assays
were used to confirm a result, and in instances where
there was a discordant result between the two tests, the
third test was used as a tiebreaker. All samples testing
HIV positive on two EIAs were subjected to a nucleic
acid amplification test (COBAS AmpliPrep/Cobas Taq-
man HIV-1 Qualitative Test, v2.0, Roche Molecular Sys-
tems, New Jersey, USA) for the final interpretation of
the test result. High Performance Liquid Chromatog-
raphy (HPLC) coupled with Tandem Mass Spectrometry
was used to test for antiretroviral analytes in HIV-
positive specimens.
Viral load testing on confirmed HIV-positive speci-
mens was performed using the recommended testing
platform for HIV-1 Ribonucleic acid (RNA) testing in
DBS samples (Abbott m2000 HIV Real-Time System,
Abbott Molecular Inc., Des Plaines, Illinois, USA).
Definition of 90–90–90 indicators
The ‘conditional’ 90–90–90 indicator is defined as:
1. First 90/Diagnosed - weighted population percent
of individuals who tested HIV positive and reported
that they knew their HIV status or had
antiretroviral analytes in their blood (numerator)
out of all individuals who tested HIV positive
(denominator).
2. Second 90/on ART - weighted population percent
of those testing positive for antiretroviral analytes
(numerator) out of all those who knew their HIV
status as defined numerator of 1 above.
3. Third 90/Virally suppressed - weighted population
percent of those who had viral loads of less than
1000 copies per ml (numerator) out of all those
who had antiretroviral analytes (denominator) as
defined numerator of 2 above.
The results are reported by sex, age, self-reported race
(black African and other), geographical type (urban,
traditional rural areas, or commercial farming communi-
ties) and by each of the nine provinces in South Africa.
Weighted population percentages of the first 90 vs the
second 90, and the second 90 vs the third 90 were plot-
ted by province and shown relative to each of the 90 tar-
gets to assess achievement of the targets provincially.
Additionally, gaps to achieving the 90–90–90 targets
were reported among all PLHIV to demonstrate the
scale of the epidemic and inform programs. The number
of individuals nationally who knew their status, those on
ART and those with viral suppression among all PLHIV
and the numbers needed to achieve the targets were esti-
mated using population weights. Similar to the national
presentation of gaps to achievement of the 90–90-90 tar-
gets, differences in percentages and numbers of
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individuals for those who knew their status, those on
ART, and those with viral suppression among all PLHIV
were estimated for each province.
Population weights based on province, sex, age, and
race were used to account for the complex survey design
and non-response, and weighted data analysis was im-
plemented using “svyset” in Stata. Estimates are reported
with 95% confidence intervals (CI) as appropriate. Stata
Statistical Software Release 15.0 (College Station, Texas:
Stata Corporation, USA) was used to conduct analyses
of the data.
Results
A total of 39,132 participants of all ages from 11,776
households were eligible to participate in the main study.
Altogether, 93.6% agreed to be interviewed and, 61.1%
agreed to provide specimens for HIV testing. Agreement
to be interviewed and to provide a blood sample varied
by sex (women - 64.3% vs men – 57.7%), age (15 to 24
years – 66.9%, 25 to 49 years old – 61.5%, 50–64 year
olds – 64.4% and 65 years and older – 69.7%), race
(Black African – 65.4%, White – 42.3%, Coloured 61.7%,
and Asian – 42.6%), and geographic area (urban –
57.3%, rural/traditional – 69.3% and commercial farm
areas – 65.1%).
Overall HIV prevalence among people aged 15 years
or older was estimated at 18.8% (95% CI 17.5–20.1%),
translating to 7,467,321 people infected with HIV in
South Africa. The 90–90–90 indicator estimates for
South Africa in 2017 were 84.8% (95% CI 81.6–87.6) of
PLHIV knew their status, of those, 70.7% (95% CI 67.6–
73.7) were on ART, and of those aware of their status
and on ART, 87.4% (95% CI 84.9–89.6) had suppressed
viral load (Table 1).
In order to achieve the 90–90–90 targets by 2020, a
total of 6,720,589 people living with HIV (PLHIV) aged
15 years and older need to be diagnosed, 6,048,530 initi-
ated on ART, and 5,443,677 of PLHIV on ART must
achieve viral suppression (Fig. 1). The gaps in the num-
bers of people along the treatment cascade in order to
achieve these were: an additional 384,585 PLHIV to be
diagnosed, an additional 1,777,710 individuals initiated
on ART, and an additional 1,742,147 PLHIV to achiev-
ing viral suppression (Fig. 1).
Proportionately, more women than men among
PLHIV knew their HIV status, 88.7% (95% CI: 85.7–
91.1) versus 78.2% (95% CI: 72.4–83.1), respectively. Of
those who knew their HIV status and who were on
ART, women were more likely than men to be virally
suppressed at 89.8% (95% CI, 87.0–92.0) versus 82.3%
(95% CI, 76.7–86.7) (Table 1, Fig. 2a-c.).
Point estimates for awareness of HIV status were
higher in older age groups: 74.0% (95% CI: 63.6–82.2),
85.8% (95% CI: 82.2–88.8), and 88.1% (95% CI: 81.7–
92.5) for 15–24 year olds, 25–49 year olds and 50–64
year olds respectively, with a slight dip, at 78.7% (95%
CI: 63.1–88.9) for 65 year olds or older PLHIV. The sec-
ond 90 target, (i.e. those on ART among those who
knew their HIV status) was the lowest, 51.7% (95% CI:
43.2–60.0) for 15–24 year olds compared to the older
age groups with the next closest age group, 25–49 year
olds at 70.5% (95% CI: 67.0–73.9). For the third 90 esti-
mate, viral suppression was near to the 90% target
(range 84.6–89.5%) for all age groups.
Among PLHIV, a higher proportion, 90.6% (95% CI:
87.0–93.4), of women aged 25–49 years old were aware
of their HIV status (i.e. 1st 90) compared to their male
peers, 77.6% (95% CI: 70.6–83.3), see Fig. 2 a. Differ-
ences were not statistically significant for men and
women in the other age categories for the first 90 esti-
mates. The trend for the first 90 among men was linear
by age category, lowest among 15–24-year olds at 68.3%
(95% CI: 55.4–79.0) to 93.9% (95% CI: 72.0–98.9) among
men 65 years and older. The trend was an inverted U-
shape for women, lowest among 15–24 year olds at
76.4%, (95% CI: 62.2–86.5) and highest among 50–64
years olds 89.8%, (95%CI: 83.3–93.9), but dropping
among 65 years and older women at 71.6%, (95% CI:
51.9–85.5).
For the second 90, those aged 15–24 years for men
and women, had the lowest proportion of individuals on
ART at 58.8% (95% CI: 41.1–74.5) and 49.1% (95% CI:
40.5–57.7), (Fig. 2b) respectively. The highest propor-
tions receiving ART was seen in females aged 25–49
years [73.7% (95% CI: 69.9–77.2)] and in older males
aged 50–64 years [87.5% (95% CI: 77.2–93.5)], males 65
years or older 86.6 (95% CI 59.1–96.6) and females 50 to
64 years old, 80.2% (95% CI 72.8–86.0).
Among PLHIV aware of their status and on ART, all
sex-age groups’ the third 90 indicators were above 80%
with the lowest at 80.5% (95% CI: 74.5–87.0) in women
aged 65 years or older and the highest in women aged
50–64 years at 92.7% (95% CI: 86.9–96.0).
The 90–90–90-point estimates for Black Africans
were, 85.3% knew their status, 70.8% were on ART and
87.3% were virally suppressed. This is in comparison
with the respective estimates of 73.1, 68.2 and 92.7% for
the other racial groups combined that include those that
self-reported as White, Coloured, or Indian. Commercial
farming communities were notable for much lower
knowledge of status than the other geographic areas,
with a 90–90–90 cascade of 56.2, 67.6, and 81.4% in
commercial farming communities compared to cascades
of 87.7, 66.5 and 87.2% in urban and 85.8, 79.8 and
88.4% in rural/traditional communities.
Geographically, the Free State Province (91.1%) had
achieved the first 90 target, and the Eastern Cape Prov-
ince (89.3%) was close to achieving the same target as
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seen in Table 1. Kwazulu-Natal (86.3%) and Gauteng
(86.5%) provinces also had fairly high rates of individuals
who knew their status, and the provinces with the lowest
percentages of PLHIV aware of their status were Lim-
popo (76.0%), the North West (77.9%), and the Northern
Cape (74.4%) (Table 1 and Fig. 3). ART coverage among
those knowledgeable of their status was highest in the
provinces of KwaZulu-Natal (79.4%) and the Eastern
Cape (76.9%), and it was lowest in the Gauteng (60.8%)
and the North West provinces (64.8%).
Figure 3 shows a plot of PLHIV aware of their status
versus those PLHIV who know their status and are on
ART by province. As no provinces have exceeded the
targeted ART coverage rate of 90%, no provinces fell
into the top two quadrants. The bottom left quadrant
shows inadequate HIV diagnosis rates and ART
Table 1 90–90 – 90 indicators for a national representative sample in South Africa, 2017 among those aged 15 years and above
Variable 1st 90 - Diagnosed & Know HIV-Positive Status 2nd 90 - on ART 3rd 90 - Virally Suppressed
% 95% CI n % 95% CI n % 95% CI n
Sex
Male 78.2 [72.4–83.1] 808 67.7 [62.2–72.7] 566 82.3 [76.7–86.7] 384
Female 88.7 [85.7–91.1] 2011 72.3 [68.9–75.4] 1681 89.8 [87.0–92.0] 1203
Age (years)
15–24 74.0 [63.6–82.2] 336 51.7 [43.2–60.0] 240 85.2 [77.3–90.6] 131
25–49 85.8 [82.2–88.8] 1959 70.5 [67.0–73.9] 1576 87.2 [84.3–89.7] 1111
50–64 88.1 [81.7–92.5] 461 82.9 [77.1–87.4] 381 89.5 [83.3–93.6] 306
65+ 78.7 [63.1–88.9] 63 82.4 [66.3–91.7] 50 84.6 [68.9–93.2] 39
Sex – Age (years)
Male 15–24 68.3 [55.4–79.0] 87 58.8 [41.1–74.5] 50 80.6 [63.2–91.0] 32
Female 15–24 76.4 [62.2–86.5] 249 49.1 [40.5–57.7] 190 87.1 [77.7–92.9] 99
Male 25–49 77.6 [70.6–83.3] 558 64.2 [57.8–70.1] 393 81.6 [74.5–87.0] 249
Female 25–49 90.6 [87.0–93.4] 1401 73.7 [69.9–77.2] 1183 89.7 [86.5–92.2] 862
Male 50–64 85.6 [74.7–92.2] 140 87.5 [77.2–93.5] 103 84.6 [73.4–91.6] 88
Female 50–64 89.8 [83.3–93.9] 321 80.2 [72.8–86.0] 278 92.7 [86.9–96.0] 218
Male 65+ 93.9 [72.0–98.9] 23 86.6 [59.1–96.6] 20 91.3 [57.4–98.8] 15
Female 65+ 71.6 [51.9–85.5] 40 79.9 [57.4–92.2] 30 80.5 [59.5–92.0] 24
Race groups
Black African 85.3 [82.1–88.0] 2573 70.8 [67.6–73.8] 2087 87.3 [84.6–89.6] 1492
Other 73.1 [54.1–86.2] 246 68.2 [54.1–79.6] 160 92.7 [84.6–96.7] 95
Geographic type
Urban area 87.7 [84.5–90.2] 1505 66.5 [62.6–70.1] 1282 87.2 [83.8–89.9] 874
Rural/Traditional 85.8 [80.3–89.9] 899 79.8 [75.0–84.0] 785 88.4 [83.7–91.9] 602
Commercial Farms 56.2 [37.7–73.1] 415 67.6 [54.9–78.2] 180 81.4 [71.4–88.5] 111
Province
Western Cape 80.9 [71.9–87.6] 223 67.2 [58.0–75.3] 163 89.0 [77.7–95.0] 100
Eastern Cape 89.3 [83.4–93.3] 325 76.9 [65.2–85.5] 282 90.4 [81.7–95.2] 207
Northern Cape 74.3 [60.9–84.2] 182 72.5 [59.0–82.8] 130 87.5 [75.0–94.2] 89
Free State 91.1 [86.0–94.5] 270 68.6 [58.0–77.6] 191 90.0 [81.3–94.9] 131
KwaZulu-Natal 86.3 [79.2–91.2] 637 79.4 [74.4–83.6] 520 85.5 [79.8–89.8] 410
North West 77.9 [59.4–89.5] 295 64.8 [57.9–71.2] 238 90.3 [84.6–94.0] 152
Gauteng 86.5 [80.5–90.9] 324 60.8 [53.3–67.7] 273 87.7 [80.7–92.3] 170
Mpumalanga 84.3 [71.5–92.0] 342 73.2 [65.8–79.6] 284 83.1 [75.4–88.8] 211
Limpopo 76.0 [55.1–89.1] 221 68.7 [58.4–77.4] 166 88.1 [81.4–92.6] 117
Total 84.8 [81.6–87.6] 2819 70.7 [67.6–73.7] 2247 87.4 [84.9–89.6] 1587
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coverage, while the bottom right quadrant shows prov-
inces that have exceeded the targeted diagnosis rates but
not ART coverage.
The third 90 target for viral suppression among those
knowledgeable of their HIV status and on ART was
achieved or close to being achieved in Western Cape
(89.0%), Eastern Cape (90.4%), North West (90.3) and
the Free State (90.0%) provinces. Only Mpumalanga
province (83.1%) had a third-90 indicator value below
85% (Fig. 4).
The number of people needed (gap) to achieve the
90–90–90 targets, are given in Table 2, while the per-
centage point gaps for achieving the 90–90–90 targets
for each province are shown in Fig. 5. The gap on the
percentage of awareness of status among PLHIV ranged
from 15.7 percentage points (or 13,872 individuals) in
the Northern Cape Province to − 1.1 percentage points
(4493 individuals above the target) in the Free State
Province. Using 81% (i.e. 1st 90*2nd 90) as the overall
ART coverage target among all PLHIV, the largest gaps
on ART coverage among PLHIV were observed in the
North West Province (34.6 percentage points, 13,1846
individuals), Limpopo Province (32.3 percentage points,
13,2937) and Gauteng Province (30.7 percentage points,
417,184 individuals) while the Eastern Cape Province
(13.0 percentage points, 98,016 individuals) and
Kwazulu-Natal Province (16.1 percentage points, 23,
3581 individuals) had the smallest gaps to achieve the
81% target.
The gap on this second 90 for the cascade has a rela-
tional influence on the third 90 or the 73% (i.e. 1st
90*2nd 90 *3rd90) target level to be achieved. Thus, the
North West Province (30.4 percentage points, 148,621
individuals), Limpopo Province (29.8 percentage points,
161,306 individuals), and Gauteng Province (28.8 per-
centage points, 452,391 individuals) had the largest gaps
to reach the 73% target for viral suppression among all
PLHIV, whereas the Eastern Cape Province again had
the lowest gap (10 percentage points, 90,351
individuals).
The highest need for diagnosis (1st 90) in terms of ab-
solute numbers was in Limpopo Province (75,782),
KwaZulu-Natal Province (62,222), North West Province
(59,155), and Gauteng Province (54,978), while the high-
est needs for ART provision were in Gauteng Province
(417,184), KwaZulu-Natal Province (233,581), Limpopo
Province (132,937), and North West Province (131,846).
Discussion
In South Africa 84.8% of PLHIV were aware of their sta-
tus, of those, 70.7% on ART, and of those knowledgeable
of their status and on ART, 87.4% had suppressed viral
load in 2017. The country had comparable figures on
these 90–90–90 indicators with neighbouring countries
for the first and third 90, while the second 90 was rela-
tively lower. In nationally representative Population-
Based HIV Impact Assessment (PHIA) surveys carried
out in several countries in the Southern Africa region in
2016/2017, the 90–90–90 indicators were: 74, 87, and
87% for diagnosed, on ART and virally suppressed re-
spectively for Zimbabwe, 73, 89, and 91% for Malawi, 85,
Fig. 1 Number of people who know their HIV status, on ART and Virally Suppressed. Numbers of individuals who know their HIV status, on ART
and virally suppressed based on the 90–90–90 targets and the gaps to achieve the targets, South Africa 2017
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87 and 92% for Swaziland, and 81, 92, and 88% for
Lesotho [20].1 Being on ART was self-reported in all
these PHIAs study countries except in Lesotho where
self-reporting was used together with laboratory detec-
tion of ART analytes among PLHIV.
The results demonstrate a significant gap in the 90–
90–90 indicator for South Africa for, ART coverage
among diagnosed PLHIV. Although the proportion of
PLHIV aware of their status who are on treatment are
higher than estimates in previous years, the current rate
of increase is not yet sufficient to meet the 90–90–90
targets. Leigh Johnson et al. estimated that 56.9% of di-
agnosed HIV adults were on ART in 2015 (Johnson,
Dorrington et al. 2017). In 2012, 31.2% or 2.0 million
PLHIV were on ART [24]. Estimated overall ART cover-
age from the latest round of this survey increased to
62.3% or 4.4 million among PLHIV by 2017. South Af-
rica adopted UTT into its treatment guidelines in Sep-
tember 2016, shortly before data collection began [17],
and the gains from this programmatic shift may not be
fully reflected in this survey. Clearly, additional
programmatic focus on the second 90, particularly
among select populations e.g. adolescents, males will be
required if the 90–90–90 targets are to be achieved.
The percentage of PLHIV who knew their status was
relatively high at close to 85% with some variation by
sex, age and geographic location. This likely includes
some individuals who were diagnosed before changes to
the UTT guidelines, who at the time of diagnosis were
not eligible for ART and have still not been initiated on
ART. It is possible that a substantial number of people
were not on treatment because they were unaware of the
new eligibility criteria or were experiencing other bar-
riers to re-engagement in care. It is important that tar-
geted programmes rapidly identify and facilitate
enrolment of these previously diagnosed individuals who
were not on treatment.
High proportions of women of reproductive age (25–
49 years old) diagnosed and on ART likely reflected in-
creased diagnosis and engagement in care due to preg-
nancy and Prevention of Mother-to-Child Transmission
(PMTCT) programmes. Interestingly, higher proportions
of men 50–64 years of age were on ART compared to
their younger counterparts. Increased engagement with
health facilities due to care-seeking for non-
communicable diseases or psychosocial factors are pos-
sible explanations for further investigation. Low
Fig. 2 a, b and c: 90–90 – 90 Indicators by Age and Sex. a. 1st 90 by Age and Sex - Percentage of PLHIV in each group aware of their HIV status, b. 2nd
90 by Age and Sex - Of those who knew their status, those who tested positive for ARVs, c. 3rd 90 by Age and Sex - Of those on ART, those who were
virally suppressed, South Africa 2017 Fig. 3: Percent of PLHIV diagnosed (1st 90) versus those diagnosed who are on ART (2nd 90), South Africa 2017
1In Zimbabwe and Malawi, the 90–90–90 targets were reported for
individuals aged 15 to 64 years old, 15 years and older in Swaziland,
similar to this study; and for Lesotho the estimates for those aged 15
to 59 years old were reported.
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treatment coverage among young people aged 15–24
years old is of concern. Women in this age group have
the highest rates of new HIV infections, (1.5% per year)
[25]. The risk of transmission in the immediate serocon-
version period is high (Pinkerton, 2007). Thus, it is im-
portant for young people to test frequently and if they
test HIV-positive, they need to be engaged in care and
treatment to reduce the risk of onward transmission.
Targeted interventions and changes to HIV programmes
may improve diagnosis and ART coverage in this age
group. Some of these are scaling up self-testing [14, 19],
home-based testing [7, 22], promoting both pre-
exposure and post-exposure prophylaxis [2], providing
youth and young-people friendly health services [12, 15]
and strengthening and streamlining linkage to care and
ART initiation [4]. A number of intervention pro-
grammes have been designed and implemented targeted
especially towards Adolescent Girls and Young Women
(AGYW). One such programme, the Determined, Resili-
ent, Empowered, AIDS-free, Mentored and Safe (DREA
MS) project was initiated in 2010 in 10 high HIV preva-
lence countries (PEPFAR, 2017f). The programme was
designed based on evidence-based health, educational
and social interventions that needed to be implemented
urgently, extensively in geographical areas that had the
greatest need, thus a broad-based approach with the
Table 2 Gaps in the number of individuals diagnosed (1st 90), on ART and virally suppressed by Province, based on the 90, 81 and
73% cascadea
Province PLHIV Gap – diagnosed Gap – on ART Gap – Viral Suppression
Western Cape 538,472 44,101 114,547 126,972
Eastern Cape 938,221 5911 98,016 90,351
Northern Cape 98,176 13,872 19,619 24,122
Free State 453,821 −4493 82,984 78,420
KwaZulu-Natal 1,868,523 62,222 233,581 284,202
North-West 543,204 59,155 131,846 148,621
Gauteng 1,745,334 54,978 417,184 452,391
Mpumalanga 680,131 34,891 113,534 140,175
Limpopo 601,441 75,782 132,937 161,306
Total 7,467,323 346,419 1,344,248 1,506,560
aDisplayed gaps in numbers are differences in counts from achieving 90% for diagnosed, 81% (i.e., 0.90 multiplied by 0.90) of all HIV infected people on ART, and
73% (i.e., 0.90 multiplied by 0.90 multiplied by 0.90) of all HIV infected individuals achieved viral suppression
Fig. 3 Percent of PLHIV diagnosed (1st 90) versus those diagnosed who are on ART (2nd 90), South Africa 2017
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main aim of reducing HIV incidence among AGYW.
The low ART uptake of ART among this group in South
Africa, which is one of the DREAMS countries, high-
lights the need for upscaling HIV Treatment Services,
demand creation, testing and counselling, linkage to care
for those who are infected, treatment, retention in care
and adherence as well as HIV prevention services across
the country especially for this group.
There is a need to understand the relatively low levels
of ART coverage given the changes in treatment guide-
lines to UTT in 2016. Previous studies found that being
diagnosed with HIV does not necessarily translate to
Fig. 5 Percentage point gaps in diagnosed (1st 90), on ART, and virally suppressed by Province
Fig. 4 Percent of PLHIV diagnosed who are on ART (2nd 90) versus percentage on ART who are virally suppressed (3rd 90), South Africa 2017
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universal uptake of ART even though one is offered
treatment [10, 11, 16]. It is not clear what the scale of
treatment refusal among PLHIV is. In a study conducted
in Soweto, Johannesburg, 20% of newly HIV diagnosed
women with low CD4 cell counts and/or who presented
with TB refused to be initiated on ART [11]. Some of
the reasons given for refusing ART initiation included
“feeling healthy”, “unable to disclose to family members”,
and “(concern about) side effects”. A study done in the
KwaZulu-Natal Province showed that linkage to care
was low for newly diagnosed individuals, students in
education institutions, and those staying far away from
health care facilities [13]. However, from the same study,
those who reported positive experiences of ART among
their close relatives and friends were more likely to
access HIV services.
Fox at el reported retention in care of 63.3% after 6
years of treatment at the national level [3]. They also re-
ported high rates of patients moving between clinics and
migration, the so called ‘silent transfer’, thus usually
resulting in under-estimation of retention rates from
clinics perspectives. The current survey used the pres-
ence of ART analytes to measure exposure to ART
which in a way measures some indication of adherence.
In the 2017/18 financial year the National Department
of Health partnered with all provincial departments of
health in the country on developing plans to improve
the 90–90–90 outcomes, and this resulted in 13 million
individuals being tested for HIV and 4.1 million individ-
uals being retained on treatment [18].
There are noticeable variations in the first two 90s,
diagnoses and ART coverage between provinces. For
example, the Eastern Cape and Free State provinces
achieved the first 90 (diagnosis), but they had low values
on the second 90 indicator, while the Northern Cape
and the North West provinces had low levels on both
the first and second 90 indicators. The same can be said
when one compares the first two 90s for geographical
areas, commercial farms had very low rates of diagnosis
and ART coverage compared to the other two geo-
graphic areas. Geographical differences in health systems
such as waiting times for patients, drug availability, staff
and system capacity to diagnose and treat more patients
need to be better understood.
It is encouraging to see that for those individuals who
were on treatment as measured by bioavailability anti-
retroviral analytes in their blood, viral suppression was high
and close to the 90% target. However, as the gap analyses
demonstrated, turning the HIV epidemic tide through con-
trolled viral suppression can only be achieved if there are
sufficiently large numbers of PLHIV who are diagnosed
who are also enrolled onto the ART programme.
Unlike other studies where self-reporting is used, the
strength of our study is that the results presented in this
study are calculated using population-based laboratory
HIV, ART and viral load testing. The estimates for ART
coverage may be lower than other studies and reflects
“on ART”. Individuals on “treatment holidays” or
defaulting for more than 14–28 days, the half-life for
most ART drugs [1], would have tested ARV negative.
Furthermore, our household-based survey captures indi-
viduals accessing care who may be missed in existing
surveillance systems such as those accessing services in
the private healthcare sector.
There are several limitations associated with this study.
Ninety four percent (94%) of survey participants agreed
to answer the questionnaire, and of these, 61% agreed to
provide blood samples for HIV testing, ART testing and
viral suppression testing. If PLHIV who provided blood
samples are different from PLHIV who were not tested,
then the presented results may be biased. Extensive
training of enumerators and undertaking multiple visits
for those not at home, up to three visits were done to in-
crease participation and minimise such biases.
Conclusion
In conclusion, South Africa has made enormous strides
to meet the 90–90–90 targets over the past 15 years, but
it still has a significant way to go to reach them espe-
cially among some sub-population groups such as ado-
lescents and young women.
Critical in achieving 90–90–90 targets is the routine
monitoring and analysis of the HIV treatment cascade
framework that tracks the delivery of services from HIV
diagnosis, linkage to care, initiation of ART, adherence
and retention in care, and viral suppression [5]. Targeted
interventions tailor-made for specific provinces and geo-
graphic areas are also needed. To provide more useful
results and recommendations that are implementable
and can be tracked, it is important to collect district and
sub-district level data so that targeted interventions can
be implemented at these levels. Those large numbers of
individuals who have defaulted on treatment as well as
those who have been tested before but were never initi-
ated on treatment should be quickly identified and
brought into treatment and care programmes via
community-based or other innovative e.g. social media,
interventions. Other factors such as substance use, poor
health status, mental health and other social/welfare fac-
tors (Bulsara, 2018) needs to be addressed if good reten-
tion in care and adherence to treatment is to be
achieved. If these individuals could return to care, more
people could be initiated on ART, and if current high
levels of viral suppression among those on ART are
maintained, then epidemic control can be achieved.
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